{
    "info": {
        "nct_id": "NCT06547112",
        "official_title": "A Pharmacodynamic Study of the Apheresis Product of Multiple Myeloma Patients Undergoing Quad-induction Followed by Motixafortide + G-CSF Mobilization",
        "inclusion_criteria": "* Subjects must be between the ages of 18 and 78 years, inclusive.\n* Histologically confirmed multiple myeloma expected to receive high-dose chemotherapy (HDT) and autologous stem cell transplantation (ASCT)\n* Received ≥3 cycles but ≤6 cycles of daratumumab-based quadruplet induction therapy (quadruplet induction therapy: combining daratumumab, a proteasome inhibitor, an IMiD, and dexamethasone) before ASCT\n* At least one week (7 days) from last induction cycle prior to the first dose of G-CSF for mobilization\n* The subjects should be in first or second CR (including CR and SCR) or PR (including PR and VGPR)\n* ECOG performance status 0 or 1\n* Adequate organ function at screening as defined below:\n\n  * White blood cell (WBC) counts > 2.5 × 10^9/L\n  * Absolute neutrophil count > 1.5 K/cumm\n  * Platelet count >100 K/cumm\n  * GFR value of ≥15 mL/min/1.732 (by MDRD equation)\n  * ALT and/or AST ≤2.5 × ULN\n  * Total bilirubin ≤2.0 × ULN unless the participant has Gilbert disease\n  * INR or PT: ≤1.5 × ULN unless participant is receiving anticoagulant therapy, as long as PT or PTT is within therapeutic range of intended use of anticoagulants\n  * aPTT: ≤1.5 × ULN unless participant is receiving anticoagulant therapy, as long as PT or PTT is within therapeutic range of intended use of anticoagulants.\n* Female subjects must be of non-childbearing potential or, if of childbearing potential, must have a negative serum pregnancy test at screening and negative urine or serum pregnancy test within 7 days prior to G-CSF first administration.\n\nNon-childbearing potential is defined as (by other than medical reasons):\n\n* ≥45 years of age and has not had menses for over 2 years\n* Post hysterectomy, bilateral oophorectomy, bilateral salpingectomy or bilateral tubal ligation at least 6 weeks prior to screening\n\n  * Women of childbearing potential must agree to use 2 methods of effective contraception: One barrier method (e.g., diaphragm, or condom or sponge, each of which are to be combined with a spermicide) and one hormonal method, unless she uses a highly effective method. Highly effective methods of contraception include:\n* Combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation: oral, intravaginal, transdermal\n* Progestogen-only hormonal contraception associated with inhibition of ovulation: oral, injectable, implantable, intrauterine device (IUD)\n* Intrauterine hormone-releasing system (IUS)\n* Bilateral tubal occlusion\n* Vasectomized partner\n* Sexual abstinence These methods must be used starting at study enrollment and for the duration of study participation through 8 days after the last dose of motixafortide.\n\nMale subjects must agree to use an adequate method of contraception (barrier method) starting with the first day of G-CSF administration through 8 days after the last dose of motixafortide.\n\n* Ability to understand and willingness to sign an IRB approved written informed consent document.\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 78 Years",
        "exclusion_criteria": "* Previous history of autologous or allogeneic-HCT\n* Failed previous HSC collections or collection attempts\n* Taken any of the listed below concomitant medications, growth factors or stimulating agents within the designated washout period:\n\n  * Dexamethasone: 7 days\n  * Thalidomide: 7 days\n  * Lenalidomide: 7 days\n  * Pomalidomide: 7 days\n  * Bortezomib: 7 days\n  * Carfilzomib: 7 days\n  * Ixazomib: 7 days\n  * G-CSF: 14 days\n  * GM-CSF or pegfilgrastim: 21 days\n  * Erythropoietin or erythrocyte-stimulating agents: 30 days\n  * Eltrombopag, romiplostim or platelet-stimulating agents: 30 days\n  * Carmustine (BCNU): 42 days/6 weeks\n* Received >6 cycles lifetime exposure to an IMiD\n* Received >8 cycles of alkylating agent combinations\n* Received >6 cycles of melphalan\n* Received prior treatment with radioimmunotherapy (e.g., radionuclides, holmium)\n* Received prior treatment with venetoclax\n* Has received a live vaccine within 30 days of the planned start of G-CSF administration. Seasonal flu vaccines that do not contain live virus are permitted.\n* Known active CNS metastases or carcinomatous meningitis\n* A history of allergic reactions attributed to compounds of similar chemical or biologic composition to motixafortide, G-CSF or other agents used in the study\n* Has an active or uncontrolled infection requiring systemic therapy\n* Has a known additional malignancy that is progressing or requires active treatment\n* Has a known underlying medical condition that, in the opinion of the treating physician or Principal Investigator, would preclude study participation.\n* Is currently participating in an investigational treatment study, or has participated in a study of an investigational agent and received study therapy, or has been treated with an investigational device, within 4 weeks prior to the first dose of treatment.\n* O2 saturation < 92% (on room air)\n* Personal history or family history of long QT syndrome or torsade de pointes\n* History of unexplained syncope, syncope from an uncorrected cardiac etiology, or family history of sudden cardiac death.\n* History of myocardial infarction, CABG, coronary or cerebral artery stenting and/or angioplasty, stroke, cardiac surgery, or hospitalization for congestive heart failure within 3 months prior to study enrollment, Angina Pectoris Class >2 or NYHA Heart Failure Class >2.\n* ECG at screening showing QTcF >470 msec and/or PR >280 msec\n* Mobitz II 2nd degree AV Block, 2:1 AV Block, High Grade AV Block, or Complete Heart Block, unless the participant has an implanted pacemaker or implantable cardiac defibrillator (ICD) with backup pacing capabilities.\n* Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial, in the opinion of the treating physician or Principal Investigator.\n* Is pregnant or breast-feeding or expecting to conceive or women of childbearing potential unless consent to use two contraceptive methods or highly effective contraception as detailed above, within the projected duration of the trial, starting with the Screening Visit through 8 days after the last dose of study drug.\n* HIV-infected if not on effective anti-retroviral therapy with undetectable viral load for 6 months. Patients with HIV who are receiving effective anti-retroviral therapy and have had an undetectable viral load for at least 6 months are eligible.\n* Evidence of chronic hepatitis B virus (HBV) that is detectable on suppressive therapy. Patients with evidence of chronic HBV infection with undetectable HBV viral load on suppressive therapy are eligible.\n* History of hepatitis C virus (HCV) infection that has not been cured or that has a detectable viral load. Patients with a history of HCV that has been treated and cured are eligible. Patients with HCV infection who are currently on treatment and have an undetectable HCV viral load are eligible.",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "Non-childbearing potential is defined as (by other than medical reasons):",
            "criterions": [
                {
                    "exact_snippets": "Non-childbearing potential",
                    "criterion": "childbearing potential",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Received ≥3 cycles but ≤6 cycles of daratumumab-based quadruplet induction therapy (quadruplet induction therapy: combining daratumumab, a proteasome inhibitor, an IMiD, and dexamethasone) before ASCT",
            "criterions": [
                {
                    "exact_snippets": "Received ≥3 cycles but ≤6 cycles of daratumumab-based quadruplet induction therapy",
                    "criterion": "daratumumab-based quadruplet induction therapy cycles received",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 3,
                                        "unit": "cycles"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 6,
                                        "unit": "cycles"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "quadruplet induction therapy: combining daratumumab, a proteasome inhibitor, an IMiD, and dexamethasone",
                    "criterion": "quadruplet induction therapy composition",
                    "requirements": [
                        {
                            "requirement_type": "components",
                            "expected_value": [
                                "daratumumab",
                                "proteasome inhibitor",
                                "IMiD",
                                "dexamethasone"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "before ASCT",
                    "criterion": "timing of induction therapy relative to ASCT",
                    "requirements": [
                        {
                            "requirement_type": "timing",
                            "expected_value": "before ASCT"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Vasectomized partner",
            "criterions": [
                {
                    "exact_snippets": "Vasectomized partner",
                    "criterion": "partner vasectomy status",
                    "requirements": [
                        {
                            "requirement_type": "vasectomized",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Platelet count >100 K/cumm",
            "criterions": [
                {
                    "exact_snippets": "Platelet count >100 K/cumm",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 100,
                                "unit": "K/cumm"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* ≥45 years of age and has not had menses for over 2 years",
            "criterions": [
                {
                    "exact_snippets": "≥45 years of age",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 45,
                                "unit": "years"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "has not had menses for over 2 years",
                    "criterion": "menses",
                    "requirements": [
                        {
                            "requirement_type": "absence_duration",
                            "expected_value": {
                                "operator": ">",
                                "value": 2,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Male subjects must agree to use an adequate method of contraception (barrier method) starting with the first day of G-CSF administration through 8 days after the last dose of motixafortide.",
            "criterions": [
                {
                    "exact_snippets": "Male subjects must agree to use an adequate method of contraception (barrier method)",
                    "criterion": "contraception use",
                    "requirements": [
                        {
                            "requirement_type": "agreement to use",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "method type",
                            "expected_value": "barrier method"
                        }
                    ]
                },
                {
                    "exact_snippets": "starting with the first day of G-CSF administration through 8 days after the last dose of motixafortide",
                    "criterion": "contraception use duration",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": "from first day of G-CSF administration through 8 days after last dose of motixafortide"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Sexual abstinence These methods must be used starting at study enrollment and for the duration of study participation through 8 days after the last dose of motixafortide.",
            "criterions": [
                {
                    "exact_snippets": "Sexual abstinence ... must be used starting at study enrollment and for the duration of study participation through 8 days after the last dose of motixafortide.",
                    "criterion": "sexual abstinence",
                    "requirements": [
                        {
                            "requirement_type": "use",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "start_time",
                            "expected_value": "study enrollment"
                        },
                        {
                            "requirement_type": "end_time",
                            "expected_value": "8 days after the last dose of motixafortide"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* The subjects should be in first or second CR (including CR and SCR) or PR (including PR and VGPR)",
            "criterions": [
                {
                    "exact_snippets": "should be in first or second CR (including CR and SCR) or PR (including PR and VGPR)",
                    "criterion": "disease response status",
                    "requirements": [
                        {
                            "requirement_type": "response category",
                            "expected_value": [
                                "first CR",
                                "second CR",
                                "CR",
                                "SCR",
                                "PR",
                                "VGPR"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* ALT and/or AST ≤2.5 × ULN",
            "criterions": [
                {
                    "exact_snippets": "ALT ... ≤2.5 × ULN",
                    "criterion": "ALT level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2.5,
                                "unit": "ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "AST ... ≤2.5 × ULN",
                    "criterion": "AST level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2.5,
                                "unit": "ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Total bilirubin ≤2.0 × ULN unless the participant has Gilbert disease",
            "criterions": [
                {
                    "exact_snippets": "Total bilirubin ≤2.0 × ULN",
                    "criterion": "total bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2.0,
                                "unit": "× ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "unless the participant has Gilbert disease",
                    "criterion": "Gilbert disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Post hysterectomy, bilateral oophorectomy, bilateral salpingectomy or bilateral tubal ligation at least 6 weeks prior to screening",
            "criterions": [
                {
                    "exact_snippets": "Post hysterectomy ... at least 6 weeks prior to screening",
                    "criterion": "hysterectomy",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "post"
                        },
                        {
                            "requirement_type": "time since procedure",
                            "expected_value": {
                                "operator": ">=",
                                "value": 6,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Post ... bilateral oophorectomy ... at least 6 weeks prior to screening",
                    "criterion": "bilateral oophorectomy",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "post"
                        },
                        {
                            "requirement_type": "time since procedure",
                            "expected_value": {
                                "operator": ">=",
                                "value": 6,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Post ... bilateral salpingectomy ... at least 6 weeks prior to screening",
                    "criterion": "bilateral salpingectomy",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "post"
                        },
                        {
                            "requirement_type": "time since procedure",
                            "expected_value": {
                                "operator": ">=",
                                "value": 6,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Post ... bilateral tubal ligation at least 6 weeks prior to screening",
                    "criterion": "bilateral tubal ligation",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "post"
                        },
                        {
                            "requirement_type": "time since procedure",
                            "expected_value": {
                                "operator": ">=",
                                "value": 6,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Histologically confirmed multiple myeloma expected to receive high-dose chemotherapy (HDT) and autologous stem cell transplantation (ASCT)",
            "criterions": [
                {
                    "exact_snippets": "Histologically confirmed multiple myeloma",
                    "criterion": "multiple myeloma",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis confirmation",
                            "expected_value": "histologically confirmed"
                        }
                    ]
                },
                {
                    "exact_snippets": "expected to receive high-dose chemotherapy (HDT)",
                    "criterion": "high-dose chemotherapy (HDT)",
                    "requirements": [
                        {
                            "requirement_type": "treatment plan",
                            "expected_value": "expected to receive"
                        }
                    ]
                },
                {
                    "exact_snippets": "expected to receive ... autologous stem cell transplantation (ASCT)",
                    "criterion": "autologous stem cell transplantation (ASCT)",
                    "requirements": [
                        {
                            "requirement_type": "treatment plan",
                            "expected_value": "expected to receive"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Female subjects must be of non-childbearing potential or, if of childbearing potential, must have a negative serum pregnancy test at screening and negative urine or serum pregnancy test within 7 days prior to G-CSF first administration.",
            "criterions": [
                {
                    "exact_snippets": "Female subjects must be of non-childbearing potential",
                    "criterion": "female subject childbearing potential",
                    "requirements": [
                        {
                            "requirement_type": "childbearing potential",
                            "expected_value": "non-childbearing"
                        }
                    ]
                },
                {
                    "exact_snippets": "if of childbearing potential, must have a negative serum pregnancy test at screening",
                    "criterion": "serum pregnancy test at screening",
                    "requirements": [
                        {
                            "requirement_type": "result",
                            "expected_value": "negative"
                        }
                    ]
                },
                {
                    "exact_snippets": "negative urine or serum pregnancy test within 7 days prior to G-CSF first administration",
                    "criterion": "urine or serum pregnancy test within 7 days prior to G-CSF first administration",
                    "requirements": [
                        {
                            "requirement_type": "result",
                            "expected_value": "negative"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* aPTT: ≤1.5 × ULN unless participant is receiving anticoagulant therapy, as long as PT or PTT is within therapeutic range of intended use of anticoagulants.",
            "criterions": [
                {
                    "exact_snippets": "aPTT: ≤1.5 × ULN unless participant is receiving anticoagulant therapy",
                    "criterion": "aPTT",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "unless participant is receiving anticoagulant therapy, as long as PT or PTT is within therapeutic range of intended use of anticoagulants",
                    "criterion": "PT or PTT (for participants on anticoagulant therapy)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": "within therapeutic range of intended use of anticoagulants"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Adequate organ function at screening as defined below:",
            "criterions": [
                {
                    "exact_snippets": "Adequate organ function at screening",
                    "criterion": "organ function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "at screening"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Subjects must be between the ages of 18 and 78 years, inclusive.",
            "criterions": [
                {
                    "exact_snippets": "between the ages of 18 and 78 years, inclusive",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "age_range",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 18,
                                        "unit": "years"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 78,
                                        "unit": "years"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* ECOG performance status 0 or 1",
            "criterions": [
                {
                    "exact_snippets": "ECOG performance status 0 or 1",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Progestogen-only hormonal contraception associated with inhibition of ovulation: oral, injectable, implantable, intrauterine device (IUD)",
            "criterions": [
                {
                    "exact_snippets": "Progestogen-only hormonal contraception associated with inhibition of ovulation",
                    "criterion": "progestogen-only hormonal contraception",
                    "requirements": [
                        {
                            "requirement_type": "association with inhibition of ovulation",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "oral, injectable, implantable, intrauterine device (IUD)",
                    "criterion": "route of progestogen-only hormonal contraception",
                    "requirements": [
                        {
                            "requirement_type": "route",
                            "expected_value": [
                                "oral",
                                "injectable",
                                "implantable",
                                "intrauterine device (IUD)"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Women of childbearing potential must agree to use 2 methods of effective contraception: One barrier method (e.g., diaphragm, or condom or sponge, each of which are to be combined with a spermicide) and one hormonal method, unless she uses a highly effective method. Highly effective methods of contraception include:",
            "criterions": [
                {
                    "exact_snippets": "Women of childbearing potential",
                    "criterion": "sex and reproductive potential",
                    "requirements": [
                        {
                            "requirement_type": "sex",
                            "expected_value": "female"
                        },
                        {
                            "requirement_type": "childbearing potential",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "must agree to use 2 methods of effective contraception: One barrier method ... and one hormonal method, unless she uses a highly effective method",
                    "criterion": "contraception use",
                    "requirements": [
                        {
                            "requirement_type": "number of methods",
                            "expected_value": {
                                "operator": "=",
                                "value": 2,
                                "unit": "methods"
                            }
                        },
                        {
                            "requirement_type": "method types",
                            "expected_value": [
                                "barrier",
                                "hormonal"
                            ]
                        },
                        {
                            "requirement_type": "alternative",
                            "expected_value": "highly effective method"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation: oral, intravaginal, transdermal",
            "criterions": [
                {
                    "exact_snippets": "Combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation",
                    "criterion": "hormonal contraception (combined estrogen and progestogen)",
                    "requirements": [
                        {
                            "requirement_type": "composition",
                            "expected_value": [
                                "estrogen",
                                "progestogen"
                            ]
                        },
                        {
                            "requirement_type": "mechanism",
                            "expected_value": "inhibition of ovulation"
                        }
                    ]
                },
                {
                    "exact_snippets": "oral, intravaginal, transdermal",
                    "criterion": "route of administration of hormonal contraception",
                    "requirements": [
                        {
                            "requirement_type": "route",
                            "expected_value": [
                                "oral",
                                "intravaginal",
                                "transdermal"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Intrauterine hormone-releasing system (IUS)",
            "criterions": [
                {
                    "exact_snippets": "Intrauterine hormone-releasing system (IUS)",
                    "criterion": "intrauterine hormone-releasing system (IUS)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* At least one week (7 days) from last induction cycle prior to the first dose of G-CSF for mobilization",
            "criterions": [
                {
                    "exact_snippets": "At least one week (7 days) from last induction cycle prior to the first dose of G-CSF for mobilization",
                    "criterion": "time interval since last induction cycle",
                    "requirements": [
                        {
                            "requirement_type": "minimum duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 7,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have maximum age of 78 Years",
            "criterions": [
                {
                    "exact_snippets": "maximum age of 78 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "maximum",
                            "expected_value": {
                                "operator": "<=",
                                "value": 78,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* GFR value of ≥15 mL/min/1.732 (by MDRD equation)",
            "criterions": [
                {
                    "exact_snippets": "GFR value of ≥15 mL/min/1.732 (by MDRD equation)",
                    "criterion": "glomerular filtration rate (GFR)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 15,
                                "unit": "mL/min/1.732"
                            }
                        },
                        {
                            "requirement_type": "calculation method",
                            "expected_value": "MDRD equation"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Absolute neutrophil count > 1.5 K/cumm",
            "criterions": [
                {
                    "exact_snippets": "Absolute neutrophil count > 1.5 K/cumm",
                    "criterion": "absolute neutrophil count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 1.5,
                                "unit": "K/cumm"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* White blood cell (WBC) counts > 2.5 × 10^9/L",
            "criterions": [
                {
                    "exact_snippets": "White blood cell (WBC) counts > 2.5 × 10^9/L",
                    "criterion": "white blood cell count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 2.5,
                                "unit": "10^9/L"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Ability to understand and willingness to sign an IRB approved written informed consent document.",
            "criterions": [
                {
                    "exact_snippets": "Ability to understand",
                    "criterion": "cognitive ability to understand informed consent",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "willingness to sign",
                    "criterion": "willingness to sign informed consent",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "IRB approved written informed consent document",
                    "criterion": "informed consent document",
                    "requirements": [
                        {
                            "requirement_type": "IRB approval",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "format",
                            "expected_value": "written"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Bilateral tubal occlusion",
            "criterions": [
                {
                    "exact_snippets": "Bilateral tubal occlusion",
                    "criterion": "bilateral tubal occlusion",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* INR or PT: ≤1.5 × ULN unless participant is receiving anticoagulant therapy, as long as PT or PTT is within therapeutic range of intended use of anticoagulants",
            "criterions": [
                {
                    "exact_snippets": "INR or PT: ≤1.5 × ULN",
                    "criterion": "INR",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "INR or PT: ≤1.5 × ULN",
                    "criterion": "PT",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "unless participant is receiving anticoagulant therapy, as long as PT or PTT is within therapeutic range of intended use of anticoagulants",
                    "criterion": "PT",
                    "requirements": [
                        {
                            "requirement_type": "therapeutic range for anticoagulant use",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "unless participant is receiving anticoagulant therapy, as long as PT or PTT is within therapeutic range of intended use of anticoagulants",
                    "criterion": "PTT",
                    "requirements": [
                        {
                            "requirement_type": "therapeutic range for anticoagulant use",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Erythropoietin or erythrocyte-stimulating agents: 30 days",
            "criterions": [
                {
                    "exact_snippets": "Erythropoietin or erythrocyte-stimulating agents: 30 days",
                    "criterion": "erythropoietin or erythrocyte-stimulating agent use",
                    "requirements": [
                        {
                            "requirement_type": "washout period",
                            "expected_value": {
                                "operator": ">=",
                                "value": 30,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Evidence of chronic hepatitis B virus (HBV) that is detectable on suppressive therapy. Patients with evidence of chronic HBV infection with undetectable HBV viral load on suppressive therapy are eligible.",
            "criterions": [
                {
                    "exact_snippets": "Evidence of chronic hepatitis B virus (HBV) that is detectable on suppressive therapy",
                    "criterion": "chronic hepatitis B virus (HBV) infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "detectability on suppressive therapy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "evidence of chronic HBV infection with undetectable HBV viral load on suppressive therapy are eligible",
                    "criterion": "chronic hepatitis B virus (HBV) infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "HBV viral load detectability on suppressive therapy",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Received >6 cycles of melphalan",
            "criterions": [
                {
                    "exact_snippets": "Received >6 cycles of melphalan",
                    "criterion": "melphalan cycles received",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 6,
                                "unit": "cycles"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Dexamethasone: 7 days",
            "criterions": [
                {
                    "exact_snippets": "Dexamethasone: 7 days",
                    "criterion": "dexamethasone administration",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": "=",
                                "value": 7,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of hepatitis C virus (HCV) infection that has not been cured or that has a detectable viral load. Patients with a history of HCV that has been treated and cured are eligible. Patients with HCV infection who are currently on treatment and have an undetectable HCV viral load are eligible.",
            "criterions": [
                {
                    "exact_snippets": "History of hepatitis C virus (HCV) infection that has not been cured",
                    "criterion": "hepatitis C virus (HCV) infection",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "cure status",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "detectable viral load",
                    "criterion": "HCV viral load",
                    "requirements": [
                        {
                            "requirement_type": "detectability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has received a live vaccine within 30 days of the planned start of G-CSF administration. Seasonal flu vaccines that do not contain live virus are permitted.",
            "criterions": [
                {
                    "exact_snippets": "Has received a live vaccine within 30 days of the planned start of G-CSF administration",
                    "criterion": "live vaccine administration",
                    "requirements": [
                        {
                            "requirement_type": "time since administration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 30,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Seasonal flu vaccines that do not contain live virus are permitted",
                    "criterion": "seasonal flu vaccine (non-live) administration",
                    "requirements": [
                        {
                            "requirement_type": "permitted",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of unexplained syncope, syncope from an uncorrected cardiac etiology, or family history of sudden cardiac death.",
            "criterions": [
                {
                    "exact_snippets": "History of unexplained syncope",
                    "criterion": "unexplained syncope",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "syncope from an uncorrected cardiac etiology",
                    "criterion": "syncope from uncorrected cardiac etiology",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "family history of sudden cardiac death",
                    "criterion": "sudden cardiac death in family",
                    "requirements": [
                        {
                            "requirement_type": "family history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Previous history of autologous or allogeneic-HCT",
            "criterions": [
                {
                    "exact_snippets": "Previous history of autologous or allogeneic-HCT",
                    "criterion": "history of hematopoietic cell transplantation (HCT)",
                    "requirements": [
                        {
                            "requirement_type": "type",
                            "expected_value": [
                                "autologous",
                                "allogeneic"
                            ]
                        },
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* GM-CSF or pegfilgrastim: 21 days",
            "criterions": [
                {
                    "exact_snippets": "GM-CSF or pegfilgrastim: 21 days",
                    "criterion": "GM-CSF or pegfilgrastim administration",
                    "requirements": [
                        {
                            "requirement_type": "washout period",
                            "expected_value": {
                                "operator": ">=",
                                "value": 21,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Personal history or family history of long QT syndrome or torsade de pointes",
            "criterions": [
                {
                    "exact_snippets": "Personal history ... of long QT syndrome",
                    "criterion": "long QT syndrome",
                    "requirements": [
                        {
                            "requirement_type": "personal history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "family history of long QT syndrome",
                    "criterion": "long QT syndrome",
                    "requirements": [
                        {
                            "requirement_type": "family history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Personal history ... of ... torsade de pointes",
                    "criterion": "torsade de pointes",
                    "requirements": [
                        {
                            "requirement_type": "personal history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "family history of ... torsade de pointes",
                    "criterion": "torsade de pointes",
                    "requirements": [
                        {
                            "requirement_type": "family history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Thalidomide: 7 days",
            "criterions": [
                {
                    "exact_snippets": "Thalidomide: 7 days",
                    "criterion": "thalidomide washout period",
                    "requirements": [
                        {
                            "requirement_type": "washout period",
                            "expected_value": {
                                "operator": ">=",
                                "value": 7,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Received prior treatment with venetoclax",
            "criterions": [
                {
                    "exact_snippets": "Received prior treatment with venetoclax",
                    "criterion": "prior treatment with venetoclax",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Is currently participating in an investigational treatment study, or has participated in a study of an investigational agent and received study therapy, or has been treated with an investigational device, within 4 weeks prior to the first dose of treatment.",
            "criterions": [
                {
                    "exact_snippets": "Is currently participating in an investigational treatment study",
                    "criterion": "participation in investigational treatment study",
                    "requirements": [
                        {
                            "requirement_type": "current participation",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "has participated in a study of an investigational agent and received study therapy ... within 4 weeks prior to the first dose of treatment",
                    "criterion": "prior participation in investigational agent study with study therapy",
                    "requirements": [
                        {
                            "requirement_type": "prior participation with study therapy",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time since participation",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "has been treated with an investigational device ... within 4 weeks prior to the first dose of treatment",
                    "criterion": "treatment with investigational device",
                    "requirements": [
                        {
                            "requirement_type": "prior treatment",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time since treatment",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Carmustine (BCNU): 42 days/6 weeks",
            "criterions": [
                {
                    "exact_snippets": "Carmustine (BCNU): 42 days/6 weeks",
                    "criterion": "prior carmustine (BCNU) therapy",
                    "requirements": [
                        {
                            "requirement_type": "washout period",
                            "expected_value": {
                                "operator": ">=",
                                "value": 42,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* G-CSF: 14 days",
            "criterions": [
                {
                    "exact_snippets": "G-CSF: 14 days",
                    "criterion": "G-CSF administration",
                    "requirements": [
                        {
                            "requirement_type": "washout period",
                            "expected_value": {
                                "operator": ">=",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has a known underlying medical condition that, in the opinion of the treating physician or Principal Investigator, would preclude study participation.",
            "criterions": [
                {
                    "exact_snippets": "Has a known underlying medical condition ... would preclude study participation",
                    "criterion": "underlying medical condition",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "impact on study participation (per physician/PI judgment)",
                            "expected_value": "would preclude study participation"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* ECG at screening showing QTcF >470 msec and/or PR >280 msec",
            "criterions": [
                {
                    "exact_snippets": "ECG at screening showing QTcF >470 msec",
                    "criterion": "QTcF interval",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">",
                                "value": 470,
                                "unit": "msec"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "ECG at screening showing ... PR >280 msec",
                    "criterion": "PR interval",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">",
                                "value": 280,
                                "unit": "msec"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* HIV-infected if not on effective anti-retroviral therapy with undetectable viral load for 6 months. Patients with HIV who are receiving effective anti-retroviral therapy and have had an undetectable viral load for at least 6 months are eligible.",
            "criterions": [
                {
                    "exact_snippets": "HIV-infected",
                    "criterion": "HIV infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "on effective anti-retroviral therapy",
                    "criterion": "anti-retroviral therapy",
                    "requirements": [
                        {
                            "requirement_type": "treatment",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "effectiveness",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "undetectable viral load for 6 months",
                    "criterion": "HIV viral load",
                    "requirements": [
                        {
                            "requirement_type": "detectability",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has an active or uncontrolled infection requiring systemic therapy",
            "criterions": [
                {
                    "exact_snippets": "Has an active or uncontrolled infection requiring systemic therapy",
                    "criterion": "infection",
                    "requirements": [
                        {
                            "requirement_type": "activity status",
                            "expected_value": [
                                "active",
                                "uncontrolled"
                            ]
                        },
                        {
                            "requirement_type": "treatment requirement",
                            "expected_value": "requiring systemic therapy"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Pomalidomide: 7 days",
            "criterions": [
                {
                    "exact_snippets": "Pomalidomide: 7 days",
                    "criterion": "pomalidomide administration",
                    "requirements": [
                        {
                            "requirement_type": "washout period",
                            "expected_value": {
                                "operator": ">=",
                                "value": 7,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Lenalidomide: 7 days",
            "criterions": [
                {
                    "exact_snippets": "Lenalidomide: 7 days",
                    "criterion": "Lenalidomide administration",
                    "requirements": [
                        {
                            "requirement_type": "washout period",
                            "expected_value": {
                                "operator": ">=",
                                "value": 7,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Received >8 cycles of alkylating agent combinations",
            "criterions": [
                {
                    "exact_snippets": "Received >8 cycles of alkylating agent combinations",
                    "criterion": "alkylating agent combination cycles received",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 8,
                                "unit": "cycles"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Eltrombopag, romiplostim or platelet-stimulating agents: 30 days",
            "criterions": [
                {
                    "exact_snippets": "Eltrombopag, romiplostim or platelet-stimulating agents: 30 days",
                    "criterion": "use of Eltrombopag, romiplostim or platelet-stimulating agents",
                    "requirements": [
                        {
                            "requirement_type": "washout period",
                            "expected_value": {
                                "operator": ">=",
                                "value": 30,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Bortezomib: 7 days",
            "criterions": [
                {
                    "exact_snippets": "Bortezomib: 7 days",
                    "criterion": "bortezomib administration",
                    "requirements": [
                        {
                            "requirement_type": "washout period",
                            "expected_value": {
                                "operator": ">=",
                                "value": 7,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has a known additional malignancy that is progressing or requires active treatment",
            "criterions": [
                {
                    "exact_snippets": "Has a known additional malignancy",
                    "criterion": "additional malignancy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "that is progressing",
                    "criterion": "additional malignancy progression",
                    "requirements": [
                        {
                            "requirement_type": "progression",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "requires active treatment",
                    "criterion": "additional malignancy treatment requirement",
                    "requirements": [
                        {
                            "requirement_type": "active treatment requirement",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known active CNS metastases or carcinomatous meningitis",
            "criterions": [
                {
                    "exact_snippets": "Known active CNS metastases",
                    "criterion": "CNS metastases",
                    "requirements": [
                        {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        },
                        {
                            "requirement_type": "knowledge status",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "carcinomatous meningitis",
                    "criterion": "carcinomatous meningitis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Carfilzomib: 7 days",
            "criterions": [
                {
                    "exact_snippets": "Carfilzomib: 7 days",
                    "criterion": "Carfilzomib administration",
                    "requirements": [
                        {
                            "requirement_type": "washout period",
                            "expected_value": {
                                "operator": ">=",
                                "value": 7,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Taken any of the listed below concomitant medications, growth factors or stimulating agents within the designated washout period:",
            "criterions": [
                {
                    "exact_snippets": "Taken any of the listed below concomitant medications, growth factors or stimulating agents within the designated washout period",
                    "criterion": "use of concomitant medications, growth factors or stimulating agents",
                    "requirements": [
                        {
                            "requirement_type": "use within washout period",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Is pregnant or breast-feeding or expecting to conceive or women of childbearing potential unless consent to use two contraceptive methods or highly effective contraception as detailed above, within the projected duration of the trial, starting with the Screening Visit through 8 days after the last dose of study drug.",
            "criterions": [
                {
                    "exact_snippets": "Is pregnant",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "breast-feeding",
                    "criterion": "breast-feeding status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "expecting to conceive",
                    "criterion": "expecting to conceive",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "women of childbearing potential unless consent to use two contraceptive methods or highly effective contraception as detailed above, within the projected duration of the trial, starting with the Screening Visit through 8 days after the last dose of study drug.",
                    "criterion": "contraception use in women of childbearing potential",
                    "requirements": [
                        {
                            "requirement_type": "contraception use",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "contraception method",
                            "expected_value": [
                                "two contraceptive methods",
                                "highly effective contraception"
                            ]
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": "Screening Visit through 8 days after the last dose of study drug"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of myocardial infarction, CABG, coronary or cerebral artery stenting and/or angioplasty, stroke, cardiac surgery, or hospitalization for congestive heart failure within 3 months prior to study enrollment, Angina Pectoris Class >2 or NYHA Heart Failure Class >2.",
            "criterions": [
                {
                    "exact_snippets": "History of myocardial infarction ... within 3 months prior to study enrollment",
                    "criterion": "myocardial infarction",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "History of ... CABG ... within 3 months prior to study enrollment",
                    "criterion": "coronary artery bypass grafting (CABG)",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "History of ... coronary or cerebral artery stenting ... within 3 months prior to study enrollment",
                    "criterion": "coronary or cerebral artery stenting",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "History of ... angioplasty ... within 3 months prior to study enrollment",
                    "criterion": "angioplasty",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "History of ... stroke ... within 3 months prior to study enrollment",
                    "criterion": "stroke",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "History of ... cardiac surgery ... within 3 months prior to study enrollment",
                    "criterion": "cardiac surgery",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "History of ... hospitalization for congestive heart failure within 3 months prior to study enrollment",
                    "criterion": "hospitalization for congestive heart failure",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Angina Pectoris Class >2",
                    "criterion": "Angina Pectoris Class",
                    "requirements": [
                        {
                            "requirement_type": "severity_class",
                            "expected_value": {
                                "operator": ">",
                                "value": 2,
                                "unit": "N/A"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "NYHA Heart Failure Class >2",
                    "criterion": "NYHA Heart Failure Class",
                    "requirements": [
                        {
                            "requirement_type": "severity_class",
                            "expected_value": {
                                "operator": ">",
                                "value": 2,
                                "unit": "N/A"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Mobitz II 2nd degree AV Block, 2:1 AV Block, High Grade AV Block, or Complete Heart Block, unless the participant has an implanted pacemaker or implantable cardiac defibrillator (ICD) with backup pacing capabilities.",
            "criterions": [
                {
                    "exact_snippets": "Mobitz II 2nd degree AV Block",
                    "criterion": "Mobitz II 2nd degree AV Block",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "2:1 AV Block",
                    "criterion": "2:1 AV Block",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "High Grade AV Block",
                    "criterion": "High Grade AV Block",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Complete Heart Block",
                    "criterion": "Complete Heart Block",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "unless the participant has an implanted pacemaker or implantable cardiac defibrillator (ICD) with backup pacing capabilities",
                    "criterion": "implanted pacemaker or implantable cardiac defibrillator (ICD) with backup pacing capabilities",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* A history of allergic reactions attributed to compounds of similar chemical or biologic composition to motixafortide, G-CSF or other agents used in the study",
            "criterions": [
                {
                    "exact_snippets": "A history of allergic reactions attributed to compounds of similar chemical or biologic composition to motixafortide, G-CSF or other agents used in the study",
                    "criterion": "allergic reactions to compounds of similar chemical or biologic composition to motixafortide, G-CSF or other agents used in the study",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial, in the opinion of the treating physician or Principal Investigator.",
            "criterions": [
                {
                    "exact_snippets": "Has known psychiatric or substance abuse disorders",
                    "criterion": "psychiatric disorders",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Has known psychiatric or substance abuse disorders",
                    "criterion": "substance abuse disorders",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "that would interfere with cooperation with the requirements of the trial, in the opinion of the treating physician or Principal Investigator",
                    "criterion": "interference with cooperation with trial requirements (due to psychiatric or substance abuse disorders)",
                    "requirements": [
                        {
                            "requirement_type": "interference with cooperation",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "determined by",
                            "expected_value": [
                                "treating physician",
                                "Principal Investigator"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Failed previous HSC collections or collection attempts",
            "criterions": [
                {
                    "exact_snippets": "Failed previous HSC collections or collection attempts",
                    "criterion": "previous HSC collections or collection attempts",
                    "requirements": [
                        {
                            "requirement_type": "outcome",
                            "expected_value": "failed"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Received prior treatment with radioimmunotherapy (e.g., radionuclides, holmium)",
            "criterions": [
                {
                    "exact_snippets": "Received prior treatment with radioimmunotherapy (e.g., radionuclides, holmium)",
                    "criterion": "prior radioimmunotherapy treatment",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* O2 saturation < 92% (on room air)",
            "criterions": [
                {
                    "exact_snippets": "O2 saturation < 92% (on room air)",
                    "criterion": "O2 saturation",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 92,
                                "unit": "%"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Received >6 cycles lifetime exposure to an IMiD",
            "criterions": [
                {
                    "exact_snippets": "Received >6 cycles lifetime exposure to an IMiD",
                    "criterion": "IMiD exposure",
                    "requirements": [
                        {
                            "requirement_type": "lifetime exposure (cycles)",
                            "expected_value": {
                                "operator": ">",
                                "value": 6,
                                "unit": "cycles"
                            }
                        },
                        {
                            "requirement_type": "IMiD type",
                            "expected_value": "IMiD"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Ixazomib: 7 days",
            "criterions": [
                {
                    "exact_snippets": "Ixazomib: 7 days",
                    "criterion": "Ixazomib administration",
                    "requirements": [
                        {
                            "requirement_type": "washout period",
                            "expected_value": {
                                "operator": ">=",
                                "value": 7,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}